Anavex Life Sciences(AVXL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVXL Anavex Life Sciences

Post-Mkt 04-29 16:18:05 EDT

3.26

-0.11

-3.26%

盘后3.26

+0.000.00%

16:10 EDT

High3.34	Low3.23	Vol618.61K
Open3.30	D1 Closing3.37	Amplitude3.26%
Mkt Cap302.11M	Tradable Cap270.74M	Total Shares92.67M
T/O2.03M	T/O Rate0.74%	Tradable Shares83.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVXL","market":"US","secType":"STK","nameCN":"Anavex Life Sciences","latestPrice":3.26,"timestamp":1777492800000,"preClose":3.37,"halted":0,"volume":618606,"hourTrading":{"tag":"盘后","latestPrice":3.26,"preClose":3.26,"latestTime":"16:10 EDT","volume":3021,"amount":9848.46,"timestamp":1777493404952,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.032640949554896236,"floatShares":83048051,"shares":92671758,"eps":-0.462642,"marketStatus":"Post-Mkt","change":-0.11,"latestTime":"04-29 16:18:05 EDT","open":3.3,"high":3.34,"low":3.23,"amount":2028580.032095,"amplitude":0.032641,"askPrice":3.32,"askSize":2999,"bidPrice":3.26,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.462642,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777507200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.37,"preHourTrading":{"tag":"盘前","latestPrice":3.31,"preClose":3.37,"latestTime":"09:29 EDT","volume":527,"amount":1805.2649554,"timestamp":1777469399999,"change":-0.06,"changeRate":-0.017804,"amplitude":0.062315},"postHourTrading":{"tag":"盘后","latestPrice":3.26,"preClose":3.26,"latestTime":"16:10 EDT","volume":3021,"amount":9848.46,"timestamp":1777493404952,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.83295,"impliedVol":1.1715,"impliedVolPercentile":0.753},"requestUrl":"/m/hq/s/AVXL/wiki","defaultTab":"wiki","newsList":[{"id":"2627441678","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere","url":"https://stock-news.laohu8.com/highlight/detail?id=2627441678","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627441678?lang=en_us&edition=fundamental","pubTime":"2026-04-14 21:15","pubTimestamp":1776172541,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, TravereWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nL6N40X0IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLG","NWMX","SPOG","DAL","CRWV","ORCL","AU","LCID","GLMD","NNOX","CWVX","TVTX","CMND","AVXL","CRWG","GSAT","KMX","AAL","EAF","GM","ORCU","F","CMPS","BE","HL","SPOT","AVNS","TSLW","TSLA","GRCE","TESL","CDE","UAL","HOTH","NEM","BLK","DOW","TE","CAT","LUV","TSLL","FRDU","TSLT","CRDO","TLA","BEZ","JNJ","TSLQ","WMG","ACI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627057448","title":"Anavex plans pivotal studies of blarcamesine targeting autism-Alzheimer’s shared autophagy dysfunction","url":"https://stock-news.laohu8.com/highlight/detail?id=2627057448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627057448?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:29","pubTimestamp":1776166147,"startTime":"0","endTime":"0","summary":"Anavex highlighted new scientific findings linking autism spectrum disorder biology with Alzheimer’s disease, strengthening rationale for its oral SIGMAR1 activator blarcamesine.No new clinical trial results were presented in this update.Anavex pointed to prior clinical evidence showing blarcamesine produced clinical effects across studies in early Alzheimer’s disease, Rett syndrome, and Parkinson’s disease dementia.Company signaled plans to advance blarcamesine into pivotal clinical studies, subject to further evaluation and regulatory considerations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief on April 14, 2026, and is solely responsible for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL22L5DR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937684","title":"Anavex Life Sciences to present at Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937684","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625937684?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:32","pubTimestamp":1775561528,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences will present at Needham 25th Annual Virtual Healthcare Conference, scheduled for April 14, 2026 at 1:30 p.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL78tY9C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623810345","title":"Anavex Life Sciences Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2623810345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623810345?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:49","pubTimestamp":1774961340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVXL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 08:49 ET (12:49 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623931219","title":"BRIEF-Anavex Life Sciences Provides Comprehensive Regulatory Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623931219","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623931219?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:58","pubTimestamp":1774871938,"startTime":"0","endTime":"0","summary":"BRIEF-Anavex Life Sciences Provides Comprehensive Regulatory UpdateMarch 30 (Reuters) - Anavex Life Sciences Corp AVXL.O:ANAVEX LIFE SCIENCES PROVIDES COMPREHENSIVE REGULATORY UPDATEANAVEX LIFE SCIENC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA1LV5FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314452","title":"Anavex keeps EMA talks after withdrawing EU blarcamesine filing for early Alzheimer’s","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314452","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314452?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:33","pubTimestamp":1774870405,"startTime":"0","endTime":"0","summary":"Anavex withdrew its EU marketing authorization application for Alzheimer’s drug candidate blarcamesine.Dialogue continues with EMA to address issues raised by CHMP as Anavex compiles additional data and analyses for early Alzheimer’s disease.Additional data was submitted to FDA to support discussions on potential pathways toward a US New Drug Application for early Alzheimer’s disease.Regulatory engagement expanded with EU authorities for blarcamesine in Parkinson’s disease and Rett syndrome.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL7yTCt8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","NDAQ","SG9999014013.SGD","BK4139","LU2210150020.SGD","SG9999014039.USD","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4588","BK4585","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314413","title":"Anavex Life Sciences Corp - Continues Dialogue With European Medicines Agency on Oral Blarcamesine for Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314413","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314413?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA1LV5FC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622825063","title":"Ema's Chmp: Application for Initial Marketing Authorisation of Blarcamesine Anavex Was Withdrawn.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622825063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622825063?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:42","pubTimestamp":1774611767,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F02Q:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622893179","title":"Anavex Life Sciences Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2622893179","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622893179?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:52","pubTimestamp":1774551120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVXL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2026 14:52 ET (18:52 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622005426","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2622005426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622005426?lang=en_us&edition=fundamental","pubTime":"2026-03-26 01:35","pubTimestamp":1774460110,"startTime":"0","endTime":"0","summary":"Maze Therapeutics  said Wednesday its experimental oral medication demonstrated a 35.6% average reduction in a key marker of kidney damage during a Phase 2 clinical trial.The stock fell 32% as intraday volume topped 6.26 million shares, compared with the daily average of 488,452.Anavex Life Sciences  withdrew its application for marketing authorization of its experimental drug blarcamesine in the EU as an add-on treatment for early Alzheimer's disease in adults.The company said the decision follows feedback from the European Medicines Agency's Committee for Medicinal Products for Human Use, indicating it would not be in a position to issue a positive opinion.The stock fell 31% as volume topped 9.92 million shares, versus the daily average of 1.38 million.Micron Technology  commenced offers to purchase six series of outstanding senior notes, with maturities ranging from 2031 to 2035.The stock fell 3.9% as volume topped 41.3 million shares, versus the daily average of almost 36.4 million","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4553","BK4532","LU0056508442.USD","LU0203347892.USD","LU2054465674.USD","BK4007","LU0082616367.USD","LU0154236417.USD","BK4141","LU0203345920.USD","BK4139","IE00B5949003.HKD","LU0889566641.SGD","BK4512","LU0274383776.USD","IE0009356076.USD","LU0081259029.USD","BK4575","LU1267930813.SGD","IE0002270589.USD","LU0127658192.USD","IE00B19Z3B42.SGD","BK4605","IE00B7SZLL34.SGD","BK4543","LU1366333091.USD","LU0642271901.SGD","LU0889565833.HKD","MAZE","GB00BDT5M118.USD","BK4566","LU2360106780.USD","LU0792757196.USD","LU1852331112.SGD","LU2211815571.USD","LU2458330169.SGD","BK4579","LU1803068979.SGD","LU1316542783.SGD","LU2048586759.USD","BK4588","LU2250418816.HKD","LU2286300806.USD","BK4527","BK4585","MULL","BK4533","LU0109392836.USD","LU2458330243.SGD","BK4554","IE00B19Z3581.USD","LU2089985449.USD","LU2931357623.SGD","LU0719512351.SGD","AVXL","LU1323610961.USD","MUD","LU0157215616.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622567073","title":"Anavex withdraws marketing authorization application for blarcamesine in the EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2622567073","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622567073?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:40","pubTimestamp":1774438845,"startTime":"0","endTime":"0","summary":"Anavex (AVXL) announced that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/anavex-withdraws-marketing-authorization-application-for-blarcamesine-in-the-eu-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/anavex-withdraws-marketing-authorization-application-for-blarcamesine-in-the-eu-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4156","AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622833078","title":"Anavex Life Sciences Corp - Withdraws EU Marketing Authorization Application for Blarcamesine","url":"https://stock-news.laohu8.com/highlight/detail?id=2622833078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622833078?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:30","pubTimestamp":1774438201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUAF9WCK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622784210","title":"Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2622784210","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622784210?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:30","pubTimestamp":1774438200,"startTime":"0","endTime":"0","summary":"NEW YORK, March  25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262094/29248/en/Anavex-Life-Sciences-Provides-Update-on-Regulatory-Review-in-the-EU-for-Blarcamesine-to-Treat-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4135","BK4139","BK4156","CNS","BK4081","EMA","AVXL","CHMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622200380","title":"Anavex Life Sciences withdraws EU marketing authorization application for blarcamesine; EMA CHMP feedback drops chances of a positive opinion","url":"https://stock-news.laohu8.com/highlight/detail?id=2622200380","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622200380?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:29","pubTimestamp":1774438199,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences withdraws EU marketing authorization application for blarcamesine; EMA CHMP feedback drops chances of a positive opinion. Anavex Life Sciences withdrew its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer’s disease in adults, narrowing its near-term regulatory pathway in the region.Feedback from the EMA’s Committee for Medicinal Products for Human Use indicated it would not be in a position to issue a positive opinion at this time, shifting the company’s focus toward additional data generation and further analyses.Chief Executive Officer Christopher U. Missling said the company plans to continue engagement with regulatory authorities, aiming to preserve longer-term commercial potential in early Alzheimer’s disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4ZGq9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702612","title":"Anavex Life Sciences Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702612","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702612?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:48","pubTimestamp":1774277280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVXL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 10:48 ET (14:48 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770203","title":"Anavex Life Sciences Presents New Data From Its Ad-004 Phase Iib/Iii Trial at Ad/Pd 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770203?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:30","pubTimestamp":1774265400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA5TSJWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621077049","title":"Anavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2621077049","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621077049?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:29","pubTimestamp":1774265382,"startTime":"0","endTime":"0","summary":"Anavex reported new analyses from the ANAVEX 2-73-AD-004 Phase IIb/III program and its ANAVEX 2-73-AD-EP-004 open-label extension in early Alzheimer’s disease, and said the results were presented at the AD/PD 2026 conference.MRI biomarker analyses showed a correlation between slowing of brain atrophy and changes on ADAS-Cog13, ADCS-ADL, and CDR-SB.In the ABCLEAR3 precision-medicine subgroup, the reported R for the relationship between atrophy slowing and ADAS-Cog13 increased from 0.23 to 0.41.Long-term data cited by Anavex indicated 77.4 weeks of “time saved” versus an ADNI control group after 144 weeks of treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2ZN5n9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429418","title":"Anavex reports blarcamesine motor function rescue in new Parkinson’s disease model at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429418","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429418?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:31","pubTimestamp":1773747087,"startTime":"0","endTime":"0","summary":"Anavex reported new preclinical data on blarcamesine in a Parkinson’s disease model combining alpha-synuclein pathology and noradrenergic degeneration. The results were presented at the AD/PD 2026 Conference. After 6 weeks of treatment, the company said blarcamesine rescued impaired motor function in the model. Anavex also reported a biomarker signal consistent with increased dopaminergic nerve fiber density in the striatum.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL12z65x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL","LU0314104364.USD","SG9999014021.USD","BK4585","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014005.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","BK4588","BK4112","IE00BGHQF748.EUR","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617636015","title":"What's Going On With Anavex Life Sciences Stock On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2617636015","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617636015?lang=en_us&edition=fundamental","pubTime":"2026-03-05 02:32","pubTimestamp":1772649120,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences' stock rises despite no news, up over 40% this year as investors watch Alzheimer's program updates and analyst targets.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/04/Dementia-In-Senior-People--Memory-Loss--.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/04/Dementia-In-Senior-People--Memory-Loss--.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51045535/whats-going-on-with-anavex-life-sciences-stock-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51045535/whats-going-on-with-anavex-life-sciences-stock-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4087","AVXL","CHMP","BK4081","BK4139","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616347945","title":"Anavex Life Sciences CEO Christopher Missling to Present at Citizens Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347945","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347945?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:31","pubTimestamp":1772541062,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp. said its President and CEO, Christopher U. Missling, will present at the Citizens Life Sciences Conference on March 10, 2026 at 11:55 a.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL53cwCh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","SG9999014013.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","BK4112","SG9999014021.USD","LU2210149790.SGD","LU2210150020.SGD","BK4139","SG9999014005.SGD","BK4588","NDAQ","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.anavex.com","stockEarnings":[{"period":"1week","weight":-0.0371},{"period":"1month","weight":0.195},{"period":"3month","weight":-0.308},{"period":"6month","weight":-0.5803},{"period":"1year","weight":-0.6482},{"period":"ytd","weight":-0.0534}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.1224},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0469},{"period":"1year","weight":0.292},{"period":"ytd","weight":0.0437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":-0.012212},{"month":2,"riseRate":0.454545,"avgChangeRate":0.117029},{"month":3,"riseRate":0.545455,"avgChangeRate":0.041572},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.057174},{"month":5,"riseRate":0.7,"avgChangeRate":0.033993},{"month":6,"riseRate":0.7,"avgChangeRate":0.16895},{"month":7,"riseRate":0.5,"avgChangeRate":-0.029973},{"month":8,"riseRate":0.4,"avgChangeRate":-0.036754},{"month":9,"riseRate":0.5,"avgChangeRate":0.010424},{"month":10,"riseRate":0.5,"avgChangeRate":-0.003565},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.028939},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.025909}],"exchange":"NASDAQ","name":"Anavex Life Sciences","nameEN":"Anavex Life Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Anavex Life Sciences(AVXL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Anavex Life Sciences(AVXL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Anavex Life Sciences,AVXL,Anavex Life Sciences股票,Anavex Life Sciences股票老虎,Anavex Life Sciences股票老虎国际,Anavex Life Sciences行情,Anavex Life Sciences股票行情,Anavex Life Sciences股价,Anavex Life Sciences股市,Anavex Life Sciences股票价格,Anavex Life Sciences股票交易,Anavex Life Sciences股票购买,Anavex Life Sciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Anavex Life Sciences(AVXL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Anavex Life Sciences(AVXL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}